Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
- Nipro Confirms Second Coronavirus Case, Again in Niigata
March 19, 2020
- RIMD, BIKEN, NIBIOHN Start Development of COVID-19 Vaccine/Test Technology
March 19, 2020
- Eiken Launches Novel Coronavirus Detection Reagent Kit
March 19, 2020
- Post-Promotion Guidelines - 1: Drug Makers Struggling to Establish Non-Sales Criteria for Rep Performance Review
March 18, 2020
- Kyorin to Develop High-Speed PCR System for Coronavirus Detection, Eyes Launch by March-End
March 18, 2020
- Chugai Recalls Herceptin over Glass Contamination
March 18, 2020
- Shionogi Seeks Collaboration with Lab Test Service Provider on Coronavirus Antibody-Test Kit in Japan
March 18, 2020
- Pfizer Joining Fray in Japan AG Market with Celecox
March 17, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Shigeo Taniuchi to Become CEO of Santen
March 16, 2020
- Japan OKs Novo’s Single-Dose Pen Devices for List-Pending Ozempic
March 16, 2020
- Daicel, AnGes/Osaka Univ. to Collaborate in Developing COVID-19 Vaccine
March 16, 2020
- PeptiDream, Mitsubishi to Launch JV to Develop Peptide Alternatives to Cell Culture Growth Factors
March 16, 2020
- Coronavirus Woes Stymie Drug Makers’ Sales Activities in Japan, Curbs on Doctor Visits Continue
March 13, 2020
- Medicago Successfully Produces COVID-19 Vaccine Candidate
March 13, 2020
- Sanofi Exploring Kevzara Use for Novel Coronavirus
March 13, 2020
- Pfizer Japan Delivers 1.1% Growth in FY2019
March 13, 2020
- Artz Battered by Deep Reduction as “G2” Price Cut Applied for Second Time
March 12, 2020
- Ninlaro Misses Primary Goal in Front-Line Myeloma Study
March 12, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…